Posted On: 10/08/2015 7:45:01 PM
Post# of 30066
Multi-Billion Dollar Tissue Engineered Skin Substitutes Market Expected Robust Growth with Latest Biotech Advancements for Treating & Restoring Damaged Tissues
CORAL SPRINGS, Florida, October 8, 2015 /PRNewswire/ --
With recent reports, studies and collaborations between cell and tissue biologists, geneticists, biotech companies and other industry experts, treatment of skin diseases and disorders fuel the development of biological substitutes to restore damaged tissue with the possibilities of actually re-growing skin or maintain tissue function. In addition to skin substitute therapies; rare disease & conditions, human genetics, cystic fibrosis and cancer immunotherapy advancements are leading the biotech sector led by Amarantus Bioscience Holdings, Inc. (OTCQX: AMBS), Pacific Biosciences of California, Inc., (NASDAQ: PACB), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), Juno Therapeutics (NASDAQ: JUNO), Nivalis Therapeutics, Inc. (NASDAQ: NVLS).
http://www.prnewswire.com/news-releases/multi...20721.html
CORAL SPRINGS, Florida, October 8, 2015 /PRNewswire/ --
With recent reports, studies and collaborations between cell and tissue biologists, geneticists, biotech companies and other industry experts, treatment of skin diseases and disorders fuel the development of biological substitutes to restore damaged tissue with the possibilities of actually re-growing skin or maintain tissue function. In addition to skin substitute therapies; rare disease & conditions, human genetics, cystic fibrosis and cancer immunotherapy advancements are leading the biotech sector led by Amarantus Bioscience Holdings, Inc. (OTCQX: AMBS), Pacific Biosciences of California, Inc., (NASDAQ: PACB), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), Juno Therapeutics (NASDAQ: JUNO), Nivalis Therapeutics, Inc. (NASDAQ: NVLS).
http://www.prnewswire.com/news-releases/multi...20721.html
(0)
(0)
